Bone remodeling involves the interplay of bone resorption and formation and is accurately controlled to maintain bone mass. Both processes require transcellular Ca 2؉ transport, but the molecular mechanisms engaged remain largely elusive. The epithelial Ca 2؉ channel TRPV5 is one of the most Ca 2؉ -selective transient receptor potential (TRP) channels. In this study, the functional role of TRPV5 in bone was investigated. TRPV5 mRNA was expressed in human and murine bone samples and in osteoclasts along with other genes involved in transcellular Ca 2؉ transport, including calbindin-D9K and calbindin-D28K, Na ؉ ͞Ca 2؉ exchanger 1, and plasma membrane Ca 2؉ -ATPase 1b. TRPV5 expression in murine osteoclasts was confirmed by immunostaining and showed predominant localization to the ruffled border membrane. However, TRPV5 was absent in osteoblasts. Analyses of femoral bone sections from TRPV5 knockout (TRPV5 ؊͞؊ ) mice revealed increased osteoclast numbers and osteoclast area, whereas the urinary bone resorption marker deoxypyridinoline was reduced compared with WT (TRPV5 ؉͞؉ ) mice. In an in vitro bone marrow culture system, the amount of osteoclasts and number of nuclei per osteoclast were significantly elevated in TRPV5 ؊/؊ compared with TRPV5 ؉/؉ mice. However, using a functional resorption pit assay, we found that bone resorption was nearly absent in osteoclast cultures from TRPV5 ؊/؊ mice, supporting the impaired resorption observed in vivo. In conclusion, TRPV5 deficiency leads to an increase in osteoclast size and number, in which Ca 2؉ resorption is nonfunctional. This report identifies TRPV5 as an epithelial Ca 2؉ channel that is essential for osteoclastic bone resorption and demonstrates the significance of transcellular Ca 2؉ transport in osteoclastic function.
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tartrate-resistant acid phosphatase ͉ 1,25(OH)2D3 ͉ osteoblast ͉ Coomassie blue ͉ laser scanning confocal microscopy M aintenance of body Ca 2ϩ is of crucial importance for many physiological functions, including neuronal excitability, muscle contraction, and bone formation. Bone is the major Ca 2ϩ storage of the body and regulates in concerted action with kidney and intestine the whole-body Ca 2ϩ balance. Transcellular Ca 2ϩ transport is an important process in maintaining Ca 2ϩ balance by these tissues (1, 2) . In bone, it is crucial for bone formation͞ mineralization to achieve adequate bone quality and strength, but also for osteoclastic bone resorption, which contributes to Ca 2ϩ balance in the blood. However, the proteins involved in transcellular Ca 2ϩ transport in bone cells are largely elusive. Recently, TRPV5 and TRPV6, members of the superfamily of transient receptor potential (TRP) cation channels, have been identified as the gatekeepers of transepithelial Ca 2ϩ transport in kidney and intestine, respectively (3) (4) (5) . These highly selective epithelial Ca 2ϩ channels are part of a three-step process, facilitating transcellular Ca 2ϩ transport (3, 4, 6) . After entry of Ca 2ϩ into the cell through TRPV5 and TRPV6, Ca 2ϩ bound to calbindin-D 28K and͞or calbindin-D 9K diffuses to the basolateral membrane. There, Ca 2ϩ is extruded via Na ϩ ͞Ca 2ϩ exchanger 1 (NCX1) and ATP-dependent plasma membrane Ca 2ϩ -ATPase 1b (PMCA1b). In a recent study, we generated mice lacking TRPV5 (TRPV5 Ϫ/Ϫ ), which displayed severe renal Ca 2ϩ wasting and compensatory intestinal hyperabsorption of Ca 2ϩ . Moreover, the knockout mice exhibited significant disturbances in bone structure, including reduced femoral cortical and trabecular bone thickness (7) .
Those findings prompted us to investigate the role of TRPV5 in bone. First, the expression of TRPV5 and the other transcellular Ca 2ϩ transporters in bone cells was studied by real-time PCR analysis and immunocytochemistry. Second, bone resorption was measured in urine, and histological analyses were carried out on femoral bones from WT mice (TRPV5 ϩ/ϩ ) and TRPV5 Ϫ/Ϫ mice. Finally, a series of bone marrow culture experiments and bone resorption assays were performed to investigate the role of TRPV5, demonstrating that in mice lacking the epithelial Ca 2ϩ channel TRPV5 bone resorption is impaired despite enhanced osteoclastogenesis. These studies exhibit an important role for TRPV5 and transcellular Ca 2ϩ transport in bone resorption.
Materials and Methods
Human Femoral Head Biopsy and Mouse Femurs. Human bone material was obtained from femoral head biopsies of ostearthritic bone. This material was collected within a clinical study, which was approved by the local medical ethical commission. Furthermore, three mice (strain B6.129) were killed to collect femurs, from which the bone marrow was flushed. The remaining bone sample was then homogenized with a Mikro Dismembrator S (Sartorius). The resulting powder was further processed for RNA isolation as described below. Culturing murine bone marrow cells has been described (8) . Cells were cultured for 6 days in the presence of 30 ng͞ml recombinant M-CSF (R & D Systems) and 20 ng͞ml recombinant murine RANKL-TEC (R & D Systems), and the media were refreshed at day 3. At the end of the human and murine cultures, cells were washed with PBS, fixed in PBS-buffered paraformaldehyde (4% vol͞vol) or formalin (10% vol͞vol), respectively, and stored at 4°C for tartrate-resistant acid phosphatase (TRACP) staining and immunocytochemistry. Alternatively, murine osteoclasts cultured on bovine cortical bone slices were lysed in water for Coomassie brilliant blue staining of resorption pits (8) .
Murine Osteoblast Cultures. Bone marrow cells were collected as described (8) . Cells were cultured in phenol-red free ␣-minimal essential medium (GIBCO͞BRL), supplemented with 100 units͞ml penicillin, 100 g͞ml streptomycin (Life Technologies, Breda, The Netherlands), 250 ng͞ml amphotericin B (Sigma), 20 mM Hepes, 1.8 mM CaCl 2 , and 15% (vol͞vol) heat-inactivated FCS (GIBCO͞BRL), pH 7.5. From day 3 onward, the culture medium was supplemented with 50 M vitamin C (Sigma) and 10 mM ␤-glycerophosphate (Sigma). At days 10 and 20 of culture cells were fixed in 70% ethanol and stained for alkaline phosphatase (ALP) and alizarin red, respectively. For ALP staining, cells were incubated in Tris⅐HCL (pH 9.5) containing 50 mM MgCl 2 , 0.6 mg͞ml bromo-chloro-indoryl phosphate (Sigma), and 150 g͞ml nitro blue tetrazolium (Sigma) for 20 min and washed with PBS. Alizarin red staining was performed, incubating the cells for 10 min in a saturated alizarin red S solution in distilled water (pH 4.2), after which the cells were washed with distilled water. The number of ALP-and alizarine red-positive colonies was counted with a microscope.
Collection of Femurs, Serum, and Urine. From 8-week-old male and female TRPV5 ϩ/ϩ and TRPV5 Ϫ/Ϫ mice, femurs (n ϭ 9) were prepared and routinely processed for plastic embedding (9) , and 10-m sections were cut. Urine was collected, and total deoxypyridinoline (DPD) cross-links were determined with the Metra DPD assay (Quidel, San Diego).
RNA Isolation, cDNA Synthesis, and Real-Time PCR. The pulverized material from the human femoral head biopsy and mouse femurs was resuspended in RNA-Bee solution (Tel-Test, Friendswood, TX), and total RNA was isolated according to the manufacturer's protocol. Human (21 days) and murine (6 days) osteoclasts were dissolved in RNA lysis buffer from the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA isolation and cDNA synthesis were performed as described (10) . Expression levels of TRPV5, calbindin-D 9K , calbindin-D 28K , NCX1, and PMCA1b were quantified by real-time PCR with an Applied Biosystems Prism 7700 sequence 
PCR primers and fluorescent probes (5Ј-6-carboxyfluorescein-and 3Ј-6-carboxytetramethylrhodamin-labeled) were designed by using the computer program PRIMER EXPRESS (version 1.5; Applied Biosystems) and were purchased from Applied Biosystems (GAPDH), Eurogentec (other human sequences), or Biolegio (Malden, The Netherlands) (mouse sequences). HPRT, hypoxantine-guanine phosphoribosyl transferase; TRPV5, transient receptor potential channel V5; CaBP, calbindin; M, murine; H, human. detection system. The expression of human GAPDH and murine hypoxanthine-guanine phopshoribosyl transferase was used as an internal control to normalize for differences in RNA extraction and degradation and for efficiency of the cDNA synthesis. The different primers and 5Ј-6-carboxyfluorescein-3Ј-6-carboxytetramethylrhodamin-labeled probes (Eurogentec, Seraing, Belgium) (Table 1) for the genes of interest were designed with PRIMER EXPRESS software (Applied Biosystems). Data are presented as relative mRNA levels calculated by the formula: relative expression ϭ 2 ⌬ Ϫ(Ct of gene of interest Ϫ Ct of household gene).
Immunocytochemistry. Murine osteoclasts were cultured as described above. Cells were fixed in 10% (vol͞vol) formalin in PBS for 10 min. The cells were incubated in 50 mM NH 4 Cl for 10 min at room temperature to reduce auto fluorescence and subsequently permeabilized with 0.1% (vol͞vol) Triton X-100 for 5 min. Next, the cells were incubated in 0.2% (vol͞vol) BSA in 1 ϫ TBS (TBS͞BSA) for 30 min followed by incubation with a polyclonal antibody raised in guinea pig directed against TRPV5 (GP3; 1:800) overnight at 4°C (11) . The next day, cells were incubated with an Alexa Fluor 488 goat-anti-guinea pig antibody (Molecular Probes) at a dilution of 1:300 for 2 h at room temperature. Finally, the cells were washed in 1 ϫ PBS and water and mounted in Vectashield containing DAPI (Vector Laboratories) for nuclear counterstaining. Pictures were taken with a Zeiss Axioplan 2 microscope. The murine osteoclast stainings were analyzed with a Leica DM IRB microscope or a Leica TCS-SP2 confocal laser scanning microscopy system (Leica Microsystems, Wetzlar, Germany). Negative controls included osteoclasts derived from TRPV5 Ϫ/Ϫ bone marrow cultures.
TRACP Staining. Femoral bone sections were stained for TRACP, using 1.1 mM Naphtol AS-BI phosphate (Sigma) as substrate, 5.2 mM pararosanilin as coupler, and 46.5 mM sodium L-tartrate as inhibitor according to Scheven et al. (12) . Fixed cells were stained for TRACP with an acid phosphatase leucocyte kit (Sigma) with small modifications. In particular, to visualize osteoclasts specifically, we used a 1 M tartrate solution instead of the supplied 0.33 M solution. The number of osteoclasts and nuclei per osteoclast were determined by two independent and blinded observers and with BIOQUANT NOVOPRIME digital-imaging software (Bioquant, Nashville, TN).
Resorption Pit Assay. Bovine cortical bone slices were sonicated in 10% (vol͞vol) ammonia (Merck) for 10 min. After extensive washing, the cells were incubated in filtered potassium aluminum sulfate (Sigma) for 10 min and subsequently stained with filtered Coomassie brilliant blue (Phastgel Blue R; Amersham Pharmacia Biotech) for 5 s. The resorption pits were analyzed with BIOQUANT software.
Statistics. In all experiments values are expressed as mean Ϯ SEM unless stated otherwise. Differences between groups were tested for significance by using the Student t test. Values were considered significantly different at P Ͻ 0.05.
Results and Discussion
The current study builds on our recent observations in the TRPV5 Ϫ/Ϫ mice (7) and demonstrates the presence of TRPV5 in osteoclasts and its functional significance for osteoclastic bone resorption.
TRPV5 Is Expressed in Human and Murine Bone Samples and Oste-
oclasts. In two different human femoral head biopsies, TRPV5, calbindin-D 9K , calbindin-D 28K , NCX1, and PMCA1b mRNA were expressed (Fig. 1A) . PBMC-derived human osteoclasts revealed mRNA transcripts for TRPV5, both calbindins, NCX1, and PMCA1b (Fig. 1B) . In contrast, TRPV5 was not detected in human osteoblasts, whereas mRNAs for calbindin-D 28K , NCX1, and PMCA1b were expressed (data not shown). In the mouse femurs mRNAs encoding TRPV5 and the other Ca 2ϩ transporters were detected (Fig. 1C) . In bone marrow-derived murine osteoclasts, TRPV5 mRNA was coexpressed with calbindin-D 28K , NCX1, and PMCA1b mRNA, but calbindin-D 9K was not detected (Fig. 1D) . As in human osteoblasts, TRPV5 mRNA was absent in cultured murine osteoblasts. Next, TRPV5 was investigated in murine osteoclasts by immunocytochemistry. Mouse tibial bone marrow cells treated with M-CSF and RANKL for 6 days and cultured on cortical bone slices showed TRACP-positive multinuclear osteoclasts ( Fig. 2A) . This finding was further substantiated by abundant expression of calcitonin receptor, which was absent in undifferentiated osteoclasts (data not shown). TRPV5 protein was evident in murine osteoclasts (Fig. 2B) . The absence of signal in osteoclasts cultured from TRPV5 Ϫ/Ϫ mice demonstrated the specificity of the TRPV5 staining (Fig. 2C) . Assessment of TRPV5 immunocytochemistry by confocal laser scanning microscopy revealed that TRPV5 staining is predominantly confined to the osteoclast ruffled border membrane (Fig. 2D) . In summary, we demonstrated the presence of TRPV5 along with the other components of transcellular Ca 2ϩ transport in osteoclasts, providing the means for transcellular Ca 2ϩ transport analogous present in the kidney (3, 6, 7).
Osteoclastogenesis Is Enhanced and Bone Resorption Is Diminished in
TRPV5 ؊/؊ Mice. After its demonstration in osteoclasts, we investigated the role of TRPV5 in osteoclastogenesis and osteoclastic bone resorption in vivo and in vitro. First, we analyzed TRACP staining in the metaphyseal area of femoral bone sections derived from TRPV5 ϩ/ϩ and TRPV5 Ϫ/Ϫ mice. The number of TRACPpositive cells was increased in the TRPV5 Ϫ/Ϫ mice compared with TRPV5 ϩ/ϩ mice ( Fig. 3 A and B) . Quantification of the TRACP staining showed a significantly increased osteoclast number (Fig.  3C ) and surface area (Fig. 3D ) in the metaphysis of TRPV5 Ϫ/Ϫ femurs. Surprisingly, urinary DPD levels were significantly reduced in TRPV5 Ϫ/Ϫ mice compared with TRPV5 ϩ/ϩ littermates (Fig. 3E ). Taken together, these data demonstrated that bone resorption is reduced in TRPV5 Ϫ/Ϫ mice, despite increased osteoclast number and size.
We further assessed the involvement of TRPV5 in osteoclast formation and function by culturing bone marrow cells from TRPV5 Ϫ/Ϫ and TRPV5 ϩ/ϩ mice with osteoclast-inducing cytokines M-CSF and RANKL. In cultures derived from TRPV5 Ϫ/Ϫ mice, the number of osteoclasts was Ϸ2-fold higher compared with TRPV5 ϩ/ϩ cultures (Fig. 4 A, B, and E) . Moreover, the number of nuclei per osteoclast was significantly increased in TRPV5 Ϫ/Ϫ osteoclasts compared with TRPV5 ϩ/ϩ osteoclasts (Fig. 4 B and F) . These data strongly support our in vivo findings (Fig. 3) that osteoclastogenesis is enhanced in TRPV5 Ϫ/Ϫ mice. Despite their increased size, osteoclasts derived from TRPV5 Ϫ/Ϫ bone marrow cells expressed similar levels of calcitonin receptor mRNA expression compared with TRPV5 ϩ/ϩ osteoclasts (data not shown). In addition, with a fluorescent phalloidin-rhodamin antibody on mature TRPV5 ϩ/ϩ and TRPV5 Ϫ/Ϫ osteoclasts, both TRPV5 ϩ/ϩ and TRPV5 Ϫ/Ϫ osteoclasts respond similarly to 10 nM human calcitonin as shown by loss of the actin ring staining within 10 min after addition (data not shown). These findings show that despite the absence of TRPV5 the osteoclasts respond normally to their major regulator of resorbing activity.
Subsequently, bone resorption was measured by a resorption pit assay based on osteoclasts derived from bone marrow cultures and seeded on cortical bone slices. In cultures of TRPV5 ϩ/ϩ osteoclasts, resorption pits were clearly observed (Fig. 4C) . However, in tibial bone marrow cultures of TRPV5 Ϫ/Ϫ mice, bone resorption was diminished (Fig. 4 D and G) . Taken together, our in vivo and in vitro findings demonstrated that bone resorption by osteoclasts lacking TRPV5 is severely impaired despite the presence of increased number and size of osteoclasts. The increase in the amount and size of osteoclasts suggests a compensatory mechanism to make up for the diminished osteoclast function. Next, we made an attempt to elucidate the mechanism of this presumed compensatory mechanism.
Diminished Resorption Does Not Enhance Osteoclastogenesis in
TRPV5 ؊/؊ Mice. It is generally accepted that an increase in ambient Ca 2ϩ concentration sensed by the calcium-sensing receptor (CaSR) on osteoclast precursors (13, 14) inhibits osteoclast formation and͞or function. Because bone resorption in the TRPV5 Ϫ/Ϫ osteoclasts is diminished, unaltered Ca 2ϩ levels may prevent CaSR activation, leading to the observed enhanced osteoclastogenesis. To explore this possibility, we examined TRPV5 ϩ/ϩ and TRPV5
Ϫ/Ϫ osteoclast formation on a plastic surface, thereby preventing resorption-induced changes in ambient Ca 2ϩ levels. Similar to bone marrow cultures seeded on bone slices, osteoclast numbers in the TRPV5 Ϫ/Ϫ cultures increased 2-fold (Fig. 5A) , and elevated numbers of nuclei per osteoclast versus TRPV5 ϩ/ϩ bone marrow cultures were observed (Fig. 5B) . These data indicated that lack of resorption and release of Ca 2ϩ did not cause the observed increased osteoclastogenesis in TRPV5 Ϫ/Ϫ mice. Early studies showed that 1,25(OH) 2 D 3 stimulates the formation of bone-resorbing osteoclasts from precursors or in cocultures of bone marrow cells and osteoblasts (15) (16) (17) (18) . Because TRPV5 Ϫ/Ϫ mice have increased 1,25(OH) 2 D 3 levels (7) and increased osteoclastogenesis in vivo, we assessed whether more osteoclast precursors exist in bone marrow of TRPV5 Ϫ/Ϫ mice explaining the observed enhanced osteoclast formation. To this end, osteoclast numbers were determined at days 1 and 2 after initiation of bone marrow cultures, when rapid expansion of precursor cells toward TRACP-positive cells becomes manifest. The amounts of TRACP-positive cells were significantly elevated at 
both time points in TRPV5
Ϫ/Ϫ cultures (Fig. 6 ), thereby providing evidence for an increased number of osteoclast precursors in the bone marrow of mice lacking TRPV5. This finding indicates that there is an enhanced and͞or accelerated osteoclast differentiation pathway in the presence of extreme high levels of 1,25(OH) 2 D 3 in TRPV5 Ϫ/Ϫ mice.
Osteoclast͞Bone Phenotype in TRPV5 ؊/؊ Mice. The findings in this study and our previous study (7) revealed that in TRPV5 Ϫ/Ϫ mice two apparently opposite phenomena are evident: disturbed bone resorption and reduced bone thickness (Fig. 7) . First, mice lacking TRPV5 display severely disturbed bone resorption as a consequence of malfunctional osteoclasts. In fact, it is intriguing why TRPV5 Ϫ/Ϫ mice do not develop osteopetrosis. Patients harboring mutations in the genes encoding the vacuolar H ϩ -ATPase and the chloride channel CLC-7 develop autosomal dominant osteopetrosis (type II benign human osteopetrosis) as a result of absent acidification of the resorption lacunae, resulting in defective bone resorption (19, 20) . In fact, in this condition osteoclast number is 3-fold increased (21) . Similarly, in our study, TRPV5 Ϫ/Ϫ mice also showed diminished bone resorption together with an increased number of osteoclasts. Despite these phenomena, no osteopetrotic phenotype (including increased cartilage remnants in the secondary spongiosa; data not shown) is observed and there is even a reduction in bone thickness (7) in mice lacking TRPV5.
First, regarding an osteopetrotic phenotype it is of interest that TRPV5 and TRPV6 have been shown to form homotetramers and heterotetramers in vitro and are highly selective for Ca 2ϩ (22) . Because TRPV6 is also expressed in osteoclasts (data not shown), it might in homotetramer form at least partly compensate for the absence of TRPV5 channels explaining the absence of an osteopetrotic phenotype. In contrast, intestine TRPV6 expression in osteoclasts derived from bone marrow TRPV5 Ϫ/Ϫ mice appeared not to be increased compared with WT osteoclasts potentially explaining the lack of full compensation of the diminished bone resorption. Second, the high 1,25(OH) 2 D 3 level found in these mice may be related to the observed bone phenotype. Despite the antirachitic nature of 1,25(OH) 2 D 3 in humans, several reports show it in mice to be negatively correlated to bone thickness. First, vitamin D receptor-ablated mice have increased cortical bone thickness (23) , and show excessive bone formation in a normal mineral condition (24) . Interestingly, long-term treatment of mice with 1,25(OH) 2 D 3 displayed a decrease in cortical thickness and cross-sectional area, but also a 50% reduction in stiffness (25) . Moreover, 1,25(OH) 2 D 3 treatment of murine osteoblasts inhibits the development of a fully mature osteoblastic phenotype as well as matrix mineralization (26) . Therefore, the role of 1,25(OH) 2 D 3 in this study in relation to the bone phenotype in our previous study (7) is explained either by increased resorption or reduced formation. Because increased resorption is unlikely as shown by this study, reduced bone formation is probably involved. We investigated osteoblast function in vitro by culturing bone marrow-derived osteoblasts from both WT and TRPV5
Ϫ/Ϫ mice for 3 weeks and stained for ALP and mineralization. WT and TRPV5
Ϫ/Ϫ osteoblast cultures contain similar amounts of ALP-and alizarin red-positive osteoblast colonies (Fig. 8) , showing that osteoblast differentiation is not intrinsically disturbed in mice lacking TRPV5. Nevertheless, because TRPV5 is exclusively expressed in osteoclasts, diminished osteoclast function may in vivo lead via an altered coupling to reduced bone formation. However, on the basis of serum osteocalcin and ALP level in TRPV5 Ϫ/Ϫ mice (7) this assumption is not clear yet.
Alternatively, in TRPV5
Ϫ/Ϫ mice, less Ca 2ϩ may be available for bone formation, as it is needed for maintenance of serum Ca 2ϩ . Further studies are obviously needed to unravel the precise relationship between 1,25(OH) 2 D 3 and bone thickness.
In conclusion, we have shown that TRPV5 and other transcellular Ca 2ϩ transporters are expressed in human and murine osteoclasts and that TRPV5 is an essential Ca 2ϩ transporter in osteoclastic bone resorption. Thus, alterations in TRPV5 function will likely have implications for metabolic bone diseases and forwards it as a possible target for therapeutic interventions. Fig. 7 . Osteoclast phenotype in TRPV5 Ϫ/Ϫ mice. The findings in this study reveal two phenomena, which contribute to the osteoclast phenotype in TRPV5 Ϫ/Ϫ mice. First, an intrinsic defect occurs in TRPV5 Ϫ/Ϫ osteoclasts, leading to a bone resorption deficit, as opposed to TRPV5 ϩ/ϩ mice. Second, priming of bone marrow by high 1,25(OH) 2D3 levels may result in more osteoclast precursors in TRPV5 Ϫ/Ϫ compared with TRPV5 ϩ/ϩ mice, leading to an increase in the amount and size of osteoclasts. 
